苯溴马隆治疗高尿酸血症临床疗效及安全性分析  

Clinical Efficacy and Safety Analysis of Benzbromarone in the Treatment of Hyperuricemia

作　　者：李华[1] 

机构地区：[1]胜利油田机关医院内科,山东东营257000

出　　处：《中国继续医学教育》2017年第33期86-87,共2页China Continuing Medical Education

摘　　要：目的探究苯溴马隆治疗高尿酸血症临床疗效及安全性。方法随机抽选2015年9月—2017年9月我院门诊收治的高尿酸血症患者86例,根据抽选顺序分为对照组43例和观察组43例,对照组实施别嘌醇治疗,观察组实施苯溴马隆治疗,比较两组疗效及安全性。结果治疗前两组患者血尿酸(SUA)、血清肌酐(Scr)及血尿素氮(BUN)水平比较,差异无统计学意义(P>0.05),治疗后两组均有改善,观察组血尿酸水平变化更为明显(P<0.05);两组治疗期间均未发生明显不良反应。结论临床治疗高尿酸血症患者采用苯溴马隆能使疗效显著提升,且安全性高。Objective To explore the clinical efficacy and safety of benzbromarone in the treatment of hyperuricemia. Methods 86 patients with hyperuricemia from September 2015 to September 2017 in our hospital were randomly selected and divided into control group 43 cases and observation group 43 cases according to the selected randomly methods, the control group received allopurinol treatment, the observation group received the treatment of benzbromarone, the efcacy and safety of the two groups were compared. Results There was no signifcant diference in the levels of serum uric acid （SUA）, serum creatinine （Scr） and blood urea nitrogen （BUN） in the two groups before treatment （P 〉 0.05）. After treatment, the two groups were improved, and the changes in the level of uric acid in the observation group were more obvious （P 〈 0.05）. There was no obvious adverse reaction during the treatment of the two groups. Conclusion The clinical treatment of patients with hyperuricemia by using benzbromarone can improve the efcacy and safety.

关 键 词：高尿酸血症 苯溴马隆 临床疗效 安全性 

分 类 号：R699[医药卫生—泌尿科学]